OSAHS

Evaluation of factors that influence the success rate of OSA treatment with a customised adjustable MAD device - a retrospective study

Giuseppe Burlon1, Michele Tepedino2, Michele Laurenziello1, Giuseppe Troiano1, Michele Cassano1, Luigi Romano3, Raffaella Rinaldi4, Domenico Ciavarella1

1 Department of Clinical and Experimental Medicine, University of Foggia, Italy; 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy; 3 Department of Otolaryngology Head and Neck Surgery, San Bassiano Hospital, Bassano del Grappa (VI), Italy; 4 Department of Anatomical, Histological, Forensic and Locomotor System Sciences, Sapienza University of Rome, Italy

SUMMARY
The aim of the present study was to evaluate how the features of obstructive sleep apnoea (OSA) and the degree of mandibular advancement influence the outcomes of oral appliance therapy with a fully-customised mandibular advancement device (MAD) in an adult population. A total of 85 adult patients with mild to severe OSA were retrospectively selected. Polysomnography was taken before treatment and after 2 months treatment with overnight MAD. Treatment success was defined as a > 50% reduction in the Apnoea/Hypopnoea Index (AHI) with a residual AHI < 10. Binary logistic regression was used to evaluate the effects of AHI, oxygen desaturation index (ODI), gender and age on the success rate of MAD therapy. MAD therapy was successful in 77.7% of patients, and the ODI was a significant predictor of treatment success. OSA treatment with the MAD was successful in reducing the AHI in adult patients. An ODI value smaller than 33.3 was a significant predictor of treatment success.

KEY WORDS: obstructive sleep apnoea, OSA, mandibular advancement, sleep parameters, oxygen desaturation index

Introduction
Obstructive sleep apnoea (OSA) is defined as a syndrome characterised by repeated collapse of the upper airways during sleep, resulting in airflow suspension that requires arousal to recover patency of the airways and
Normal breathing. A diagnosis of OSA is confirmed after overnight polysomnography, when an Apnoea-Hypopnoea Index (AHI, number of apnoea/hypopnoea events per hour of sleep) greater than 5 and a complaint of daytime sleepiness are observed. Hypoxaemia/hypercapnia derived from the reduced airflow, fragmented sleep caused by frequent arousals, exaggerated fluctuations in heart rhythm, blood pressure and intrathoracic pressure are responsible for severe sequelae like cardiovascular morbidity and mortality, neurocognitive impairment, systemic inflammation, increased risk of driving accidents and poorer quality of life. It is a significant health-related problem that affects 5.9% of women and 12.5% of men in the general population over 40 years. A study on an Italian population reported a prevalence of 2.7% in a range between 30 to 69 years of age.

The treatment options for this kind of patients comprise behavioural changes (e.g., weight loss and reduced consumption of alcohol), sleep position training, continuous positive airway pressure (CPAP), mandibular advancement devices (MAD) and upper airway surgery. According to the Practice Parameters of Care of the American Academy of Sleep Medicine (AASM), CPAP is the gold standard for treatment of OSA in adult patients, particularly for moderate to severe cases. CPAP therapy is currently provided by the Italian National Health Service, being introduced among the Essential Levels of Care since 2017. This welfare policy is based on a concept of health that has evolved considerably: it is no longer about being healthy and disease-free, but rather about thorough well-being from physical, psychological and social perspectives.

Thus, the Italian healthcare system guarantees potentially universal access to care, without any distinction of personal and social conditions. However, nonadherence to CPAP treatment is high, and therefore MAD therapy is recommended by the AASM as a first-line treatment in mild to moderate OSA cases or as an alternative therapy for severe cases, non-compliant with CPAP. A MAD acts by forcing the mandible to a forward position, thus increasing the upper airway’s volume by widening the velopharynx, stabilising the soft palate and hyoid bone, stretching the tongue muscles and preventing the posterior rotation of the mandible. Although CPAP is more effective in reducing the AHI, this difference is overcome by greater compliance and acceptance of MAD therapy.

The results of a systematic review demonstrated that different types of MADs have different efficacy in terms of mandibular protrusion and reduction of OSA events, with fully customisable devices showing superior performance. While there is consensus on a comparable efficacy in AHI reduction between CPAP and MAD in mild to moderate OSA patients, there is still some uncertainty regarding severe OSA patients: while some authors reported promising results for severe OSA patients, a systematic review of the relevant literature was unable to perform a subgroup analysis to evaluate the efficacy of MAD therapy related to OSA severity. In addition, the current literature provides only a limited number of studies that describe the amount of mandibular advancement, considered as an important factor for both treatment outcomes and side effects.

The aim of the present retrospective study was to evaluate how OSA features and the degree of mandibular advancement influence the outcomes of oral appliance therapy with a fully-customised MAD in an Italian adult population.

Materials and methods

This retrospective study was carried according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. The records of OSA patients treated at a University Dental Clinic, from January 2011 to January 2018, were screened for the following inclusion criteria:

- Epworth Sleepiness Scale > 10;
- diagnosis of OSA confirmed by an overnight polysomnography;
- results of drug-induced sleep endoscopy (DISE) confirming the positive effect of mandibular advancement on airway obstruction;
- overnight MAD therapy with a fully-customisable device (Protrusor®, nonrusso+®, Dr Giuseppe Burlon, Belluno, Italy);
- age > 20 years old;
- a follow-up of 2 months with polysomnographic evaluation;
- completeness of diagnostic records.

Exclusion criteria were: smoking habit, BMI greater than 34 kg/m², previous surgical treatment of the maxillofacial complex or the upper airway, presence of fixed oral appliance or mobile prosthetic rehabilitation, patients in treatment with CPAP or nCPAP, patients with severe cardiovascular disease, presence of temporomandibular joint disorder.

The procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 1983. The records were retrieved retrospectively, analyzed anonymously and patients signed written informed consent to participate to future research at the time that the records were taken. The Protocol was approved by the Ethics Committee of the University of L’Aquila, Italy (protocol no. 9032).
To detect a moderate to small effect size (0.3) having a type error of 0.05 and a power of 0.8, 64 subjects were needed. For all patients, data on AHI and the 3% Oxygen Desaturation Index (3% ODI, number of desaturation events greater than 3% of the baseline value per hour of sleep) were retrieved from pre-treatment (T0) polysomnography. According to AASM guidelines, patients with an AHI between 5 and 15 were defined as mild OSA, patients with an AHI ranging between 15 and 30 were defined as moderate OSA, while those with an AHI greater than 30 were considered to have severe OSA. For mild to moderate OSA patients, MAD therapy was the first-choice of treatment, while severe OSA patients started MAD therapy after non-adherence to CPAP therapy.

**Instrumental evaluation**

Each patient received complete overnight polysomnography (PSG). All subjects were evaluated for one night in a sleep laboratory using a portable device, the Embletta system (Flaga, Reykjavik, Iceland). The recording was performed after one night of adaptation to the hospital setting. The airflow was monitored by a nasal cannula and by an oral thermistor. The thoracic-abdominal movements of all subjects were detected through two piezoelectric belts. Overnight continuous recordings of oxygen saturation were obtained by finger pulse oximetry. Snoring was recorded by a microphone placed at the neck, and note was taken of ECG findings and sleep position.

Apnoea was defined as the cessation of airflow lasting 10 sec; and hypopnoea was defined as a discrete reduction (two-thirds) of airflow and/or abdominal rib-cage movements lasting 10 sec associated with a > 3% decrease in oxygen saturation. The number of events per hour was obtained by dividing the total number of events by the total sleep time (TST) and was defined as the AHI. The oxygen desaturation index (ODI) was also measured, as were the number of arterial oxyhemoglobin saturation dips ≥ 3%. Nocturnal hypoxaemia was evaluated in terms of percentage of total sleep time with oxyhaemoglobin saturation < 90%.

Sleep apnoea was defined using AHI ≥ 10 per hour. The test was repeated with oral appliance three months later in all patients.

Patient enrolled in the present study had previously had a DISE to evaluate the collapse area. In the operating room, electrocardiography, pulse oximetry, non-invasive blood pressure and bispectral index (BIS) were monitored. Propofol was used during DISE. Propofol 2 mg/kg was intravenously administered at DISE start; 1 mg/kg was given for maintenance. The maximum dosage of propofol was 3 mg/kg. A flexible fiberoptic endoscope (Type ENF-GP, Olympus Europe GmbH, Hamburg, Germany) was introduced by one experienced ENT surgeon in the awake patient to evaluate the awake upper airway state.

When target sedation was reached, a soft mandibular protrusion was produced by use of a protrusor appliance.

**The device**

The MAD used for the present study is a customisable and adjustable device. It is composed of two resin splints connected by two threaded titanium bars with two titanium screw each, which constitutes the protrusive component of the device (Figs. 1, 2). The head of the titanium screws allows for lateral movements of the mandible, while keeping the mandible in a forward and lower position. The titanium bars have laser marks every 2 mm to facilitate the titration of the degree of mandibular advancement.

**Treatment protocol**

All patients were instructed to wear the MAD: an initial mandibular advancement of 70% of the total possible

![Figure 1. The Protrusor® MAD device. It is made of two resin splints connected by two threaded titanium bars, which can be regulated to reach the desired amount of mandibular advancement. A chip for compliance monitoring is embedded in the lower resin splint.](image)

![Figure 2. The Protrusor® MAD device in place after individual titration.](image)
protrusive movement was set using intraoral gauge (Occlusion®, nonrusso+®, Dr Giuseppe Burlon, Belluno, Italy) (Fig. 3). During the following visits every 15 days, the therapeutic mandibular protrusion was adjusted on an individual basis with 1 or 2 mm increments, until the most comfortable position that allowed improvement of symptoms was reached: this position was established based on the symptoms reported by patients and their bed partner. The amount of the final mandibular advancement was recorded for each patient as a percentage of the maximal protrusive movement achievable.

Post-treatment (T1) AHI and 3% ODI values were retrieved from another polysomnography after a period of 2 months of treatment.

The therapy was considered successful based on the residual AHI value: patients showing ≥ 50% AHI reduction compared to baseline and a T1 AHI ≤ 10 were considered good responders. On the other hand, patients showing a reduction < 50% of AHI, but with a residual AHI > 10 were considered bad responders and unsuccessful cases.

**Statistical analysis**

For AHI and 3% ODI values, the T1-T0 difference was also calculated and reported both as a raw value and a percentage of the T0 value. Descriptive statistics and overall success rate were calculated. A Shapiro-Wilk normality test was used to evaluate the distribution of all variables. Binary logistic regression was performed to study the effects of age, gender, AHI value at T0, ODI 3% at T0, and mandibular advancement on being classified as a good or a bad responder. The predictors were included in the model with a forward stepwise method. The first type error was set as P < 0.05.

**Results**

Complete records for 85 patients were available out of the 150 initially screened; the remaining incomplete diagnostic records of the other subjects were excluded from further study. The study sample was composed of 72 males (mean age 55.3 ± 12.3) and 13 females (mean age 65.5 ± 7.9); other demographic characteristics are reported in Table I. Based on the T0 AHI value, 26 patients were classified as mild OSA, 36 patients as moderate OSA, and 23 patients as severe OSA.

Descriptive statistics are reported in Table I. According to the criteria reported in the Materials and methods, 66 patients were considered good responders and 19 patients poor responders. Therefore, the treatment was considered successful in 77.7% of patients. All patients showed good compliance with MAD therapy. Some of the severe OSA patients who initially refused CPAP, but whose MAD therapy was unsuccessful, returned to CPAP therapy after the period considered for the present study. No side effects on the temporo-mandibular joint (TMJ) were reported by any patient.

The logistic model was able to correctly predict 81.2% of cases. The regression model included only the variables ODI 3% at T0 and the Constant (Tab. II), whereas the other predictors were not significant and were excluded by the forward stepwise method (Tab. III). The odds ratio for the ODI 3% variable was 0.92, meaning that a 1-point decrease of ODI multiplies the odds of being a good responder by 0.92. The calculated critical value for ODI 3% was ODI < intercept/coefficient = 3.36/0.09 < 33.3. Therefore, an ODI value smaller than 33.3 was needed to be classified as a good responder.

**Discussion**

MADs are a valuable treatment modality for patients with OSA: several reports have confirmed they are associated with improvement in the quality of life, daytime sleepiness, cardiac autonomic function, and functional and cognitive outcomes that are comparable to CPAP therapy. The results of the present study showed that MAD therapy with the customised adjustable device studied can successfully treat 77.7% of adult patients. Comparing our data with the existing literature is not simple because there is large heterogeneity in the parameters used to consider a treatment successful or not. Some authors reported a success (defined as post-treatment AHI < 10) rate of 72% when using a customised non-adjustable MAD. Other authors observed clinical success (defined as post-treatment AHI < 10) in 54% of adult patients. Fernandez-Julian et al. reported...
Outcome-related factors for MAD therapy

successful (AHI < 10 and Epworth Sleepiness Score < 10) treatment in 50% of adult patients with moderate to severe OSA. Mints et al. showed a higher success (defined as post-treatment AHI < 10) rate of 80% using a customised adjustable appliance in a sample of 510 patients comprising mild, moderate and severe OSA, and concluded that treatment success is not dependent on the baseline degree of severity of OSA. This finding is in contrast with our results: a significant (P = 0.001) effect of baseline 3% ODI value on treatment success was found (Tab. II). Higher values of 3% ODI predicted an unsuccessful treatment outcome, with a calculated threshold value of 33.3 oxygen desaturation events per hour of sleep. The 3% ODI value was a stronger predictor than the AHI value, the latter being excluded from the regression model due to collinearity (0.792) with the 3% ODI variable.

These results appear to confirm current guidelines suggesting MAD treatment as the first choice therapy for mild to moderate OSA patients, and as an alternative to CPAP for severe OSA. The main advantage of MADs, even in severe OSA patients, is its significantly higher compliance and self-reported usage compared to CPAP. On the other hand, OSA treatment with MAD is also associated with some side effects. In the short term, muscular and articular tenderness, gingival irritation, mouth dryness and excessive salivation can occur: these side effects can be easily managed and even prevented. Regarding TMJ pain, it has been reported in the literature in 12.5% of patients, and usually manifests in the early phases of treatment. A study on FEM models revealed that the TMJ does not experience significant stress, regardless of the amount of mandibular advancement, suggesting that the TMJ discomfort referred by patients could be due to altered muscle dynamics, since the forward posturing of the mandible increases muscular activity.

On the other hand, long-term side effects are more complex and involve skeletal and dental modifications. The mechanism behind these changes is the same as those described for orthodontic functional appliances: when the muscles are stretched by the device due to the forward posturing of the mandible, forces are transmitted to the bones and the teeth, and the long duration of these forces produces changes in skeletal morphology and teeth position. The dental and skeletal changes are progressive, and thus patients should be monitored over time, and are also dependent on the duration of the MAD therapy. In the present study, no relevant short-term side-effects were reported, while long-term effects could not be evaluated.

### Table I. Descriptive statistics for good responders and bad responders.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Good responders (n = 66) Mean ± SD</th>
<th>P value*</th>
<th>Poor responders (n = 19) Mean ± SD</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>55.9 ± 12.4</td>
<td>0.012</td>
<td>59.9 ± 11.3</td>
<td>0.108</td>
</tr>
<tr>
<td>AHI T0</td>
<td>19.9 ± 12.3</td>
<td>&lt; 0.001</td>
<td>31.2 ± 11.1</td>
<td>0.900</td>
</tr>
<tr>
<td>AHI T1</td>
<td>3.7 ± 3.4</td>
<td>&lt; 0.001</td>
<td>18.1 ± 10.2</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>AHI T1-T0</td>
<td>-16.1 ± 11.9</td>
<td>&lt; 0.001</td>
<td>-13.1 ± 10.9</td>
<td>0.661</td>
</tr>
<tr>
<td>AHI T1-T0 %</td>
<td>69.6 ± 24.4</td>
<td>&lt; 0.001</td>
<td>63.6 ± 28.7</td>
<td>0.012</td>
</tr>
<tr>
<td>3%ODI T0</td>
<td>18.8 ± 10.6</td>
<td>0.011</td>
<td>30.6 ± 12.1</td>
<td>0.713</td>
</tr>
<tr>
<td>3%ODI T1</td>
<td>5.1 ± 3.9</td>
<td>&lt; 0.001</td>
<td>20.8 ± 12.3</td>
<td>0.293</td>
</tr>
<tr>
<td>3%ODI T1-T0</td>
<td>-13.2 ± 10.9</td>
<td>0.002</td>
<td>-9.8 ± 13.5</td>
<td>0.168</td>
</tr>
<tr>
<td>3%ODI T1-T0 %</td>
<td>66.5 ± 22.9</td>
<td>0.006</td>
<td>54.1 ± 30.3</td>
<td>0.075</td>
</tr>
<tr>
<td>Advancement (%)</td>
<td>80.1 ± 14.9</td>
<td>&lt; 0.001</td>
<td>77.9 ± 15.6</td>
<td>0.105</td>
</tr>
</tbody>
</table>

*: P value from the Shapiro-Wilk normality test.

### Table II. Stepwise binary logistic regression (n = 85).

<table>
<thead>
<tr>
<th>Variable</th>
<th>B</th>
<th>S.E.</th>
<th>Wald</th>
<th>df</th>
<th>P value*</th>
<th>Exp(B)</th>
<th>95% CI for Exp(B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3% ODI T0</td>
<td>-0.09</td>
<td>0.03</td>
<td>11.24</td>
<td>1</td>
<td>0.001</td>
<td>0.92</td>
<td>0.87 to 0.96</td>
</tr>
<tr>
<td>Constant</td>
<td>3.36</td>
<td>0.74</td>
<td>20.62</td>
<td>1</td>
<td>&lt; 0.001</td>
<td>28.8</td>
<td></td>
</tr>
</tbody>
</table>

### Table III. Variables excluded from the binary logistic regression model (n = 85).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Score</th>
<th>Df</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>3.079</td>
<td>1</td>
<td>0.079</td>
</tr>
<tr>
<td>Gender</td>
<td>0.085</td>
<td>1</td>
<td>0.770</td>
</tr>
<tr>
<td>AHI T0</td>
<td>0.155</td>
<td>1</td>
<td>0.694</td>
</tr>
<tr>
<td>Advancement %</td>
<td>1.384</td>
<td>1</td>
<td>0.239</td>
</tr>
<tr>
<td>Overall statistics</td>
<td>4.935</td>
<td>4</td>
<td>0.294</td>
</tr>
</tbody>
</table>
The present study demonstrated that this is not a parameter that influences clinical outcomes of therapy (Tab. III). On the contrary, some authors reported that greater mandibular advancements were more effective in improving polysomnographic parameters. However, Lamont et al. observed that for some OSA patients, excessive mandibular advancement causes an increase in airway obstruction. Other authors recommended MAD treatment with an advancement of no more than 50% of the maximum protrusive movement, because greater advancements did not produce further improvements in AHI reduction. The results of the present study seem to confirm that titration of mandibular advancement through subsequent steps is important, because each patient has their own therapeutic mandibular position that should be recognised, a position that does not necessarily coincide with the maximum achievable protrusion.

Other factors like the patient’s age and gender were not significant predictors of the success of MAD treatment, confirming the findings of other studies. The main limitation of the present study is its retrospective nature. We took care to avoid any selection bias, and all patients with incomplete records were excluded. Another limitation is the short follow-up, which precludes us from making statements on the long-term success of MAD therapy with the proposed device. Possible future improvements of the present protocol could be evaluation of other patient related parameters such as body mass and neck circumference, and assessment of quality of life, since other parameters in addition to AHI can explain the clinical success of therapy. Further studies could also take into account skeletal features and volumetric assessment of the upper airway.

Conclusions
The MAD studied was effective in reducing the AHI value below 10 in 77.7% of patients in a population of adults with mild to severe OSA. The main predictor of the success of MAD treatment was a 3% ODI value below 33.3.

References


